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Junru Cui, M.S.
University of Connecticut, 2011
Cell migration is a basic biological process that is fundamental to several normal and
disease processes such as embryonic development, tissue repair, immune function,
angiogenesis and cancer cell invasion and metastasis. Small organic molecules inhibiting
cell migration can be used as both research probes and therapeutic agents. DX-52-1, a
semisynthetic derivative of the natural product quinocarmycin (also known as
quinocarcin), inhibits the migration of Madin-Darby canine kidney epithelial cells with
nanomolar concentration. We have identified galectin-3, a multifunctional protein whose
best-known function is its sugar binding ability, as a secondary target of DX-52-1 with
functions in cell motility. In addition, we have identified HUK-921, another small
molecule with antimigratory activity that has far greater selectivity for galectin-3 over
radixin both in vitro and in cells. Neither of them targets the carbohydrate-binding site of
galectin-3, moreover,

results indicate that functions of galectin-3 required for cell

migration are independent of carbohydrate binding ability. We investigated the effects of
the two inhibitors on cell migration and proliferation in different cancer cell lines and
discovered that DX-52-1shows promising potency in serveral of the tested ones especially
triple negative human breast cancer BT20 and MDA-MB-231 cells, suggesting this small
molecule has a great potential to treat cancers. Six DX-52-1 analogs were synthesized and
structure-activity relationship (SAR) studies were carried out in cell migration and in vitro
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competitive binding assays. We provided strong evidence that the mechanism of covalent
modification of galectin-3 involves elimination of the nitrile group of DX-52-1 followed
by an attack of a nucleophilic amino acid side chain of galectin-3 on the resulting iminium
ion. We proposed the similar mechanism for alkylation of radixin by DX-52-1.
Furthermore, we demonstrated that the hydroxyl group (-OH) of DX-52-1(C-19) plays an
important role in recognition of DX-52-1 and target proteins.
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CHAPTER I
INTRODUCTION TO CHEMICAL GENETICS AND CELL MIGRATION

1.1 Chemical genetics: A brief overview
Small molecules are useful tools for studying and regulating the functions of biological
macromolecules such as proteins and nucleic acids. Scientists, using the classical method,
focus on the effect of small molecules on genes, and then they go from genotype to
phenotype or oppositely to find the desired information. While classical genetics is
tremendously powerful, there are certain complementary advantages of the chemical
genetics. Scientists have been making lots of great achievements by using the classical
method, however, this approach is labor intensive, unable to correlate the target gene with
the protein product precisely because proteins usually undergo post-translational
modification before they fully function; furthermore, it brings consequent problems by
affecting the abundance of target proteins. For this concern, chemical genetics or chemical
biology, a new method, has been developing in the past twenty years by which researchers
can focus on the effects of the small molecules on the proteins of interest directly and be able
to either enrich our knowledge on life science or benefit the development of new drugs thus
it attracts more and more attention and grows fast as world spreads. For being more efficient,
high-throughput methodologies are used to allow for the rapid screening of large collections
of small molecule compounds with a desired biological activity in chosen biological assays.
Subsequent mode of action studies then reveal the identification and functions of the targets
of those hits that are compounds showing activities. Both methods afford the opportunity to
discover new components of biochemical pathways.
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Chemical genetics is an approach that utilizes small molecules, coupled with highthroughput screening methodologies, to discover and regulate the function of biological
macromolecules, which allows for directly perturbing the protein functions using small
molecules in a living biological system, rather than indirectly manipulating their genes
through mutation. The small molecules can be added or washed out at desired times,
therefore providing much more precise information over when and how the function is
inhibited. Furthermore, classical genetics is only able to be applicable to a limited number of
organisms for genetic analysis, while chemical approaches do not have this bottleneck and
can be applied to any cell type or even the whole-organism where the “drug” delivery is
accessible. Even though there are several drawbacks for broader application of this method,
there are also a few recent advances and efforts that have been facilitating to overcome these
problems (for reviews, see refs. [1-4]). Some of these achievements include: (1) the
completion of human genome project and the development of protein data bank which
provide information to identify or verify gene products potentially involved in pathogenesis
and design small molecules that modulate their function; (2) small molecule libraries with
great structural and functional diversity generated using combinatorial synthesis largely
increase the possibility that specific compounds with potential druggability can be screened
out; and (3) the development in chromatographic and mass spectrometric techniques,
coupled with other labeling methods, which have remarkably increased the accuracy and
sensitivity of small-molecule target identification.
1.1.2 Forward and reverse chemical genetics
Classical genetics have been traditionally divided into two types, forward and reverse
approach. Forward genetics, which involves large-scale random mutations of selected
2

genome, followed by screening and identification of the target gene responsible for the
phenotypic aberration, meanwhile, reverse genetics, which involves mutation of the gene
of interest first and then characterization of any resulting mutant phenotype. Therefore,
forward genetic analysis proceeds from phenotype to genotype, whereas reverse genetics
proceeds oppositely. With direct evolution from classical genetics, chemical genetics can
be categorized as forward and reverse approaches as well. In spite of the target difference,
both methods require a collection of small molecules with vast diversity and complex, also
known as compound libraries, as well as high-throughput screening assays. The sources of
the compound libraries can be either synthetic compounds or sometimes natural products,
or combined sometimes. Synthetic organic chemists have been developing methods to
produce large collections or libraries of “natural product-like” small molecules through
diversity-oriented synthesis (DOS) [5] to strengthen traditional target-oriented synthesis
(TOS) [6]. Ideally, DOS leads to effective parallel synthesis of compound libraries in order
to develop better applications and is an attention-getting area of synthetic chemistry or
medical chemistry [5, 7, 8].
Forward chemical genetics involves screening of the libraries of small molecules with a
desired activity or phenotypic effect on biological processes of a chosen system, usually
cultured cells but also in organisms such as zebrafish embryo system [9]. The molecular
targets, proteins in most cases, will be identified following the identification of the
bioactive small molecules. This method has been leading to the identification of new
proteins in several biological processes and the generation of compounds for drug
development (for reviews, see refs. [2, 10, 11]) (Figure 1). What challenges the most in
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Figure 1.1. General schematic of the chemical genetic process. Forward
chemical genetics involves screening compound libraries in cells or organism in
order to identify the hits, small molecules that induce a phenotype change, and
lead to identification of the molecular targets of the small molecules is in
succession. Meanwhile, in reverse approach, researchers screen small molecule
libraries in biochemical assays using known protein targets to identify compounds
that regulate the function of the protein; the small molecule regulators are then
applied to investigate the phenotypic effect in a cellular or organismal model.
this method is likely to be the identification of target protein of the hits, bioactive small
molecule. An affinity-based method followed by a Gel-based MS method are generally
used to purify and identify the target proteins, in which the bioactive compound can be
fixed onto a solid support or attached with a tag or label (for instance, biotin, radioisotope
or fluorophore) without losing the ability binds the protein[12]. In addition, new methods
such as the nucleic acids microarrays and the yeast two-hybrid system have been being
developed to facilitate target identification [13-16]. This method is more welcomed used in
academia to widen our knowledge towards understanding how proteins work in a
biological system.
4

On the other hand, small molecule libraries are screened against known protein of interest,
kinase most likely, to identify compounds that regulate the function of the target protein
through binding or disrupting in reverse chemical genetics. As such regulators are
identified and verified, they can then be tested in living cells or organisms to investigate
the function of that protein in vivo (Figure 1). This approach, thus, favors the large scale of
drug discovery efforts in pharmaceutical industries, rather than in an academic lab where a
relatively small number of validated drug targets are available, a much more collection of
proteins can be tested without being limited.

1.2 Cell migration
Cell migration is a multi-step process that involves dynamic assembly and disassembly of
cytoskeleton, attachment and detachment to extracellular proteins, and translocation of the
cell, which plays a fundamental role in many processes that include embryonic
development, tissue repair, immune function, and angiogenesis. It takes place during the
whole process of embryonic and tissue development; for instance, the process of
gastrulation in which a gastrula develops from a blastula by the inward migration of cells,
in detail, large amount of cells inside the blastocyst change their adhesive properties and
migrate collectively to form the three germ layers that build up the fundamental body plan
of the organism [17, 18]. Cell shape change and motility are also crucial to some biological
processes such as inflammation and immune function [20-25]. Moreover, cell migration
also plays important role in diseased processes such as cancer cell invasion and metastasis.
For example, during metastasis, tumor cells move out of the initial location and enter the
blood stream and then migrate to a new site to spread the tumors (for reviews, see refs.
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[26,27]). Thus, inhibition of cell migration holds a promise of therapeutic intervention in
treatment of these diseases.

1.2.1 Cell sheet migration during epithelial wound closure
Epithelial cells are bound together to form sheets through several kinds of interactions such
as tight junctions, adherens, gap junctions and desmosomes that provide an excellent
model system for studying both cell migration and cell-cell interactions. Cell-sheet wound
closure assays can be initiated by scratching a wound on a monolayer of cultured cells.
Cells then respond to the “wounding” by migrating into together to form the monolayer
again in order to “heal” the wound. In widely used cell-cell adherent cells, such as the
Madin-Darby canine kidney (MDCK) cells, they move with multiple rows of cells actively
contributing to cell sheet movement through protrusive cell crawling as a sheet of cells in a
cohesive and coherent manner without losing cell-cell contacts [28, 29]. Collective
migration of a continuous cell sheet is a common mode of cell migration during
development, tissue repair and even in the invasion and metastasis of certain cancers (for a
review, see ref. [30]). Movement of the cell sheet during wound closure assays in cultured
epithelial cells has a noticeable similarity to cell sheet movement in vivo during the
reepithelialization component of wound healing and during embryonic morphogenesis,
such as in dorsal closure in Drosophila (for reviews, see refs. [31-33]), ventral enclosure in
Caenorhabditis elegans (for a review, see ref. [34]) and eyelid closure in the mouse foetus
(for a review see [33]).

1.2.2 Molecular mechanisms controlling cell sheet migration during wound closure
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Originally, the fundamental cornerstone for understanding cell sheet migration derives
from investigation on the movement of single cell that crawls individually, not as
collectives. Abercrombie and colleagues brought up the modern concept of cell migration
on animal cells [35-40]. They defined the asymmetric morphology of a moving cell, which
has a broad, flattened sheet of cytoplasm, protrudes at the leading edge of the migrating
cell is the primary “engine” of motility. Later on, researchers referred it to as a lamella,
lamellipodium or leading-edge protrusion and the following studies have led to a
recognition of subcellular domains of different structure and function within this protrusion
from its very front tip to farther back towards the cell body [41]. The ruffling of the plasma
membrane is a characteristic feature of many actively migrating cells and related to
lamellipodia. They curl up above the plane of the cell and flow backward toward the cell
body as turnovers; membrane ruffles are presumptive protrusions that allow cells to attach
and move in three-dimensional environments [35].
The cytoskeleton, a network which functions as the “skeleton” or “scaffolding” of the cell
to control cell shape, contains three polymer systems: actin filaments, intermediate
filaments and microtubules. It presents in all cells and locates in the cytoplasm, plays
important roles in both intracellular transport (the movement of vesicles and organelles, for
example) and cellular division. Dynamic polymerization and depolymerization of actin is
the driving force for cell motility [42-55]. Microtubles are highly dynamic tubular
structures and play a crucial role in generation and maintenance of polarity in epithelial
cells, which are preconditions to lead to cell movement [56, 57]. Apart from that,
microtubles also play important roles in cell migration through direct and indirect
connections with actin cytoskeleton [57-62]. Both of them are remarkably important to
7

various other biological processes such as cell division [63]. Whereas intermediate
filaments, a family of related proteins forming the most heterogeneous filament system, are
not considered to be an essential active element of cell motility, they interact with cell
adhesion molecules and other cytoskeletal systems and play critical roles in maintaining
the mechanical properties of cells and tissues and in the process of signal transduction [6466].
Cell migration is now considered as a dynamic cyclic process [44]. This cycle is triggered
by responding to external signals to change the polarity of the cells by which cells extend
protrusions or lamellipodia in the direction of migration by assembling G-actin to F-actin.
And the system continues to polymerize actin in the direction of movement in order to
provide driving force. New adhesion sites needed for traction are established at the leading
edge protrusion, anchoring the protrusion to the substratum. In many cases, actin-myosin
(actomyosin) filament-based contraction drives the cell body forward, which is led by the
direction of the protrusion. Detachment of adhesions at the cell rear edge and retraction of
the trailing edge or “tail” of the cell completes the cycle as a whole process (for reviews,
see refs. [45, 47-51, 53-55, 67-71]) (Figure 2). The cell moves as cycles repeat.
Dynamic assembly of F-actin at the front of leading edge of the cell and disassembly of Factin and regeneration of and recycling of G-actin behind the lead edge is the driving force
of crawling animal cells. Many of other proteins such as alpha-actinin, beta-spectin and so
on that interact directly or indirectly with actin are also required for initiation and
persistence of cell migration, and some of these proteins will be described further below.
The ability of polarized cells to move largely relies on the formation and structure of Factin and other proteins associated with the actin network at leading-edge protrusions. The
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formation of lamellipodial protrusion is tightly correlated with the ongoing actin
polymerization near the leading-edge plasma membrane. Actin filaments (F-actin), polar

Figure 1.2. A migrating animal cell [69]. A migrating cell needs to perform a
coordinated series of steps to move. It begins with the cell’s response to an
external signal that leads to the polarization, extension of a leading edge
protrusion or lamellipodium, formation of new cell adhesions sites which attach
the leading edge protrusion to the substratum on which the cells is moving, cell
body contraction, and detachment of adhesions at the cell rear. Nucleation of new
actin filaments, actin polymerization (formation of filamentous actin or F-actin
from ATP-bound monomeric actin or G-actin) at the barbed end, filament crosslinking, network disassembly, dissociation of G-actin (actin depolymerization) at
the pointed end, cell-substratum adhesion, cell body contraction, and tail
retraction occur concurrently in different parts of the cell and are controlled by
other proteins to generate productive, net forward movement.
polymers with variable length, have a fast-growing “barbed” end or plus end (a term based
on its appearance when myosin head fragments are bound to the filament) and a slowgrowing “pointed” end or minus end. Polymerization is both kinetically and
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thermodynamically favored at the barbed end over at the pointed end. Actin
polymerization occurs when G-actin-ATP complex binds to the end of an actin filament
(Figure 1.3). In the Mg2+-ATP-rich cytoplasm of a cell, F-actin and G-actin are maintained
in a dynamic steady state, and thus polymerization is a highly controlled process at the
leading-edge protrusions of the cell [72]. The intracellular concentration of G-actin is
maintained above the critical concentration (effectively, the Kd) of the barbed end, but
below that of the pointed end, which ensures one-way growth from the barbed end alone
under required conditions. The flux of ATP-G-actin association onto available barbed ends
is balanced by the dissociation of actin monomers from the pointed ends. The process has
been referred to as treadmilling [72], filament length remaining nearly constant but the
filament appearing to move forward, that is relative to any attached point outside of the
cell. Polymerization at the leading edge supplies the force to form protrusion to “push” the
plasma membrane forward (for reviews, see refs. [68, 69, 73]).

Figure 1.3. A process of actin polymerization G-actin (globular actin) with
bound ATP can polymerize, to form F-actin. F-actin hydrolyzes its bound ATP to ADP +
Pi and release Pi. ADP release from the filament does not occur because the cleft opening
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is blocked. ADP/ATP exchange: G-actin can release ADP and bind ATP, which is usually
present in the cytosol at higher concentration than ADP.
As well as assembly, F-act disassembly is critical for cell motility since it allows recycling
G-actin from rear portions of the lamellipodia to the front. G-actin bound to Mg2+-ATP has
a high affinity for the barbed ends of F-actin. After binding the barbed end, actin catalyzes
the hydrolysis of the γ-phosphate group of the bound ATP. Conversion of ATP-actin to
ADP-actin causes a conformational change in the actin molecule which results in lowering
affinity between subunits and monomer dissociation. Since G-actin binds at the barbed end
in the ATP-bound state, the barbed end is ATP-actin-rich and more stable, while the
pointed end more ADP-actin-rich and less stable.
Proteins with F-actin binding and severing activity include gelsolin [153,154], villin [155],
adseverin [156], actin-depolymerizing factor [157,158] and cofilin [159] that bind to actin
filaments and modulate their length by breaking them into shorter fragments and
facilitating dissociation of actin monomers from the pointed end. Cofilin/actindepolymerizing factor (ADF) is such protein whose activity is regulated by reversible
phosphorylation. In detail, cofilin binds aside of actin filaments and leads to dissociation of
monomers from the pointed end through distortion of the helical twist that facilitates this
process [49, 74, 75]. The dissociation of ADP-actin from the pointed end regenerates a
pool of G-actin for additional polymerization. Another major actin filament severing
protein, gelsolin, functions in a similar way as cofilin except its severing activity relies on
a critical concentration of Ca2+ (>10−6 M) to take apart actin networks (for reviews, see
refs. [68, 69, 73]).
The fact that thymosin β4 (TB4), the main actin-sequestering protein in cells, its ability to
11

bind to G-actin (but not F-actin) can also favor disassembly of F-actin by lowering the
concentration of free G-actin around the barbed end. Thus, it forms a complex with G-actin
with a ratio of 1:1 to inhibit spontaneous nucleation [76]. Profilin, unlike TB4, favors
assembly of F-actin by competing with TB4 for binding to ATP-G-actin in a ratio of 1:1.
Profilin appears to promote this function in multiple ways [77]. Firstly, profilin promotes
the exchange of ADP for ATP on G-actin to accelerate the replacement of the pool of
polymerization-competent ATP-G-actin [78]. Secondly, it acts as a specific carrier of Gactin and dissociates from G-actin only when the complex has bound the barbed end [78].
Therefore, profilin further emphasizes the preference of G-actin for the barbed end.
Interestingly, profilin has something in common with thymosin β4 in which it also inhibits
spontaneous nucleation of actin filaments [76, 79, 80]. Thymosin β4 and profilin thus
ensure that polymerization of actin only occurs when specific nucleating factors or preexisting free barbed ends are available. In addition, certain proline-rich proteins, such as
Ena/VASP, aid in delivering the profilin-ATP-G-actin complex to the sites at barbed ends
where polymerization occurs and thereby further facilitate actin filaments assembly [81].
The correlation of Ena/VASP in the process of forming a filopodium (thin, finger-like
actin-based projections) has also been demonstrated by analyzing various mutants of
Ena/VASP and their localization to both the leading edge of protruding lamellipodia as
well as filopodial tips [82-85]. The formation of F-actin at the barbed end is
physiologically terminated when capping proteins bind to the end to sterically stop further
binding of ATP-G-actin (for review, see refs. [68, 69, 73]).
The mechanisms of actin polymerization can be categorized into three kinds: (1) de novo
nucleation of new filaments from G-actin, which tends to occur at the plasma membrane;
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(2) dissociation of capping proteins from filament barbed ends; and (3) severing of
filaments, which generates a new free barbed end in addition to a pointed end. The de novo
nucleation that is regulated by multiple actin-nucleating factors including the actin-related
protein (Arp) 2/3 complex [86], formins [87], Spir [88], and Cordon-Bleu [89, 90]. The
first class of de novo actin nucleators to be identified was a seven-polypeptide complex,
Arp2/3. During initiation of de novo nucleation, Arp 2/3 complex remains attached to the
pointed end, allowing G-actin to be added to the newly created barbed end. The actin
filaments that extend from polymerization are orthogonally crosslinked in lamellipodia or
bundled in filopodia by different actin-binding proteins such as actinin and vinculin to
yield organelle-excluding F-actin gels with suitable strength to support protrusion [91-94].
Actin capping and severing proteins keep the actin filaments short, while Arp2/3 keeps
initiating new branches that grow to drive the cell moving forward at the leading edge of
lamellipodial protrusion. When activated by a nucleation promoting factor (NPF), the
Arp2/3 complex binds to the side of existing filament therefore new filaments are
o

nucleated at a ~70 angle from the sides of existing ones in vitro and in vivo; this appears to
initiate the formation of crosslinked actin networks in lamellipodia. Binding of actino

crosslinking proteins such as filamin, a Y-shaped dimer that imparts a ~90 angle between
two crosslinked actin filaments, stabilizes an orthogonal orientation of filaments and
dramatically stiffens the actin gel [91]. It has been argued that the observed network of
short, branching actin filaments would be more effective to drive the leading edge forward
than unbranched filaments, given the flexibility of actin filaments [95-99].
The nucleation core of the Arp 2/3 complex needs to be activated by one of several NPFs
such as the WASP family proteins, which include Wiskott-Aldrich Syndrome protein
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(WASP), neural WASP [100], and the related WASP-family verprolin-homologous
(WAVE) proteins [101-103], leading to the stimulation of actin polymerization and
assembly [92, 104]. The C-terminal region of both WASP and WAVE contain a verprolin
homology domain (V domain) that interacts with actin monomers, while the cofilin
homology sequence (C domain) associates with the Arp2/3 complex to create a nucleation
core. One major difference between the two scaffolding proteins is that WASP contains a
GTPase-binding domain for the small GTPases Cdc42 and Rac which are upstream
regulators of actin assembly, while WAVE does not. WASP and WAVE normally exist in
an auto-inhibited conformation with the verprolin homology, cofilin homology, and acidic
region (VCA) domains of the C terminus folded onto the rest of the peptide sequence,
preventing actin and the Arp 2/3 complex from association [103].
The formins, another family of actin assembly factors that are single polypeptide of a
multi-domain complex, nucleate unbranched actin filaments in stress fibers and filopodia
while the Arp2/3 complex nucleates the branched ones [87,105]. Usually, the FH2 domain
in the complex is responsible for actin nucleation and remains attached at the barbed end of
actin filament after nucleation and moves processively as it elongates, keeping away the
capping proteins [106]. The degree of activity varies largely even though they share a lot of
similarities on basic properties [105].
The Spir protein is another family of actin nucleators that are first identified in Drosophila
[88, 107]. They are monomeric as formins. Spir proteins are characterized by the presence
of four WASP homology 2 (WH2) domains that bind actin. Unlike the Arp2/3 complex,
Spir does not rely on the presence of WASP-related NPFs to be functioned during the
nucleation of actin filaments. Interestingly, the WH2 domains are also found in the Arp2/3
14

complex but not able to facilitate actin polymerization. Spir binds to the pointed end of
newly formed actin filaments like the Arp2/3 complex does but it contributes nothing to
the branched filament networks as the Arp2/3 complex [88, 107]. Recently Cordon-Bleu
(Cobl) has been characterized as the fourth class of actin assembly protein that nucleates
actin and may drive morphogenesis of the central nervous system during development as
well. Cobl is a brain-enriched protein contains three WH2 domains, which are responsible
for actin binding and nucleation [89].
Vast arrays of other proteins show both actin-binding and actin-regulatory abilities also
exist. For instance, the ERM family proteins including ezrin, radixin, and moesin proteins
are membrane-associated proteins that bind to actin (for reviews, see refs. [108-110]).
They function as linkers bridging the membrane and cytoskeleton in actin-rich cell surface
structures like microvilli, membrane ruffles and other protrusions and are hence considered
to play essential roles in the regulation of cell morphology and motility. Each of the ERM
proteins contains three structural domains: the N-terminal FERM domain (named after the
proteins band 4.1, ezrin, radixin and moesin) that binds to the membrane-associated
proteins, the α-helical central domain and the C-terminal domain (CTD) that binds to actin
[111]. ERM proteins exist in a closed inactivated form in which the FERM and CTD bind
each other in a head-to-tail manner, thereby preventing them from interacting with their
individual binding partners [112]. Phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) binds
to the FERM domain and then phosphorylates C-terminal threonine to separate the headto-tail form therefore the ERM proteins switch to a open state to be fully functioned. In the
open state, ERM proteins act as linkers to connect actin filaments to membrane through
integral membrane proteins such as CD43, CD44, and intracellular cell adhesion molecules
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(ICAM1-3) or membrane channels and receptors, such as the Na+/H+ exchanger-3
(NHE3) and various β2-adrenergic receptor (for reviews, see refs. [109, 110, 113, 114]).
Integrins, transmembrane proteins, are the major actin-linked cell adhesion proteins that
attach the cell to the extracellular matrix (ECM) via binding to the actin cytoskeleton
indirectly and facilitate traction during cell migration. The association between the cell and
the ECM may assist the cell to endure the driving forces of motility without being torn out
of the ECM. The transient attachments to the matrix during movement are mediated
primarily by integrin proteins at sites called focal complexes [61], which are generated
following interaction of integrins with ECM, then their clustering. The clusters likely
provide sufficient intracellular binding sites to aid in forming the stable signaling
complexes on the cytoplasmic side of the cell membrane, which are related to the more
stable focal adhesions at the termini of stress fibers in stationary adherent cells [115,
116]. Cells attach to a substrate via the interaction of their integrins. When moving, the
driving forces help the cell relocate to the substrate at its leading edge and concurrently
release those at its rear edge. When released from the substrate, integrins are transported
back into the cell by endocytosis; they are then brought through the cell body to its front by
the endocytic cycle where they are added back to the surface to start a new cycle,
facilitating the cell to make fresh attachments at its leading front in this manner repeatedly
(shown in Figure 4, [121]). Integrins are heterodimers containing two subunits alpha and
beta. They also function as cell surface receptors for a number of extracellular matrix
proteins, which is critical for cell movement [117]. Their cytosolic domains bind to several
adaptor proteins, such as talin, vinculin, α-actinin (an actin-bundling protein), and filamin
A [118-120]. These adaptor proteins are regulated by focal adhesion kinase, integrin-linked
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kinase, and phosphatidylinositol-3-kinase, which have also been shown to be involved in
cell migration [116].

Figure 1.4. A schematic diagram shown for endocytosis and recycling of intergrins in
cell migration. Cells attach to a substrate via the interaction of their integrins. When
moving, the driving forces help the cell relocate to the substrate at its leading edge and
concurrently release those at its rear edge. When released from the substrate, integrins are
transported back into the cell by endocytosis; they are then brought through the cell body
to its front by the endocytic cycle where they are added back to the surface to start a new
cycle, facilitating the cell to make fresh attachments at its leading front in this manner
repeatedly.

1.2.3 Chemical modulators of cytoskeletal dynamics and cell motility
There are some small molecules that show regulatory activity in cytoskeletal dynamics and
cell migration. Among them, some are used as drugs to treat diseases or cancers. For
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instance, colchicine and colcemide are two natural products that are used to treat some
diseases by inhibiting tubulin polymerization and disrupt microtubles [122,123]. Both of
them have also displayed activity in inhibition of cell migration in different cell types and
systems [124-131]. Moreover, two of these microtuble-targeted drugs, colchicines and
taxol

(which

stabilizes

the

polymerization

of

tubulin)

are

used

in

cancer

chemotherapy[122,123,132] and the detailed information of these and other inhibitors can
be found in ref. [69].
As to actin, there are three types of direct small-molecule modulators: (1) destabilize actin
filaments, (2) stabilize actin filaments, and (3) distupt the interaction of actin-binding, and
actin-regulatory proteins of actin skeleton. Cytochalasin B, cytochalasin D, and latrunculin
A are some of the cell-permeant destabilizers of actin filaments (for a review, see ref.
[69]). Cytochalasins function as barbed-end capping proteins, to bind and block the barded
end of F-actin so that they inhibit the dynamic assembly of F-actin. [133-136]. On the
contrary, phalloidin, a bioactive component extracted from deadly mushroom Amanita
phalloides, can stabilize F-actin [137] and has long been conjugated with fluorophore to
visualize F-actin in fixed cells [138]. However, the poor permeability of phalloidin makes
its usefulness as a functional cellular probe limited. Luckily, jasplakinolide (jaspamide) has
been discovered as a F-actin-stabilizing small molecule and highlighted by its great
permeability [139].
Unlike the notable amount of small molecules that directly regulate the functions of actin
and microtubule, small molecules that interact with actin-binding proteins and other
regulators of actin function and cell migration are very few. The known ones include
blebbistatin, regulating the function of class-II skeletal muscle myosins [140]; ML-9, a

18

synthetic compound, inhibiting myosin light chain kinase (MLCK) [141]; Y-27632,
derivative from synthetic pyridine, is an inhibitor of Rho-associated kinase (Rho-kinase)
[142]; and wiskostatin, a chemical inhibitor of N-WASP [143]. In addition, we have
discovered small molecules that target different proteins involved in cell migration and
identified their targets [144-152].
This thesis directly addresses the application of a forward chemical genetics approach to
use DX-52-1, a novel inhibitor of cell migration, as a power tool to define the roles of its
target protein galectin-3 in the processes of cell migration and cell adhesion; the
application of SAR study to the study of mechanism of action of this inhibitor with its
target proteins; and the investigation of its sensitivity and specificity on eleven cancer cell
lines.
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CHAPTER II
SMALL MOLECULE INHIBITORS DX-52-1 AND HUK-921 SHOW DIFFERENT
SENSITIVITY AND SELECTIVITY IN DIFFERENT CANCER CELL LINES AND
SAR STUDY REVEALS THE MECHANISM OF ACTION OF DX-52-1

Summary
Small molecules that inhibit cell migration have potential as both research probes and
therapeutic agents. Two small molecules DX-52-1 and HUK-921were previously reported
to show anti-migratory activity in Madin-Darby canine kidney (MDCK) epithelial cells
with promising potency, yet the mechanism has remained unclear. In this study, DX-52-1
and HUK-921 were used as probes to investigate their selectivity and sensitivity on eleven
different cancer cell lines including human breast cancer, human prostate cancer, human
melanoma and mouse breast cancer cells in the fundamental processes such as cell
migration and cell proliferation. We discovered that DX-52-1 has promising anti-migratory
and anti proliferation activity in T47D, MDA-MB-435 and BT-20 cells (nanomolar) and
MDA-MB-231, 4T1, B16-F10 and B16-BL6 cells (low micromolar) whereas HUK-921
showed lower potency compared to that of DX-52-1. Further studies suggest that DX-52-1
has no effect on either the overall expression of radixin and galectin-3 or in the cellular
localization of galectin-3 in different cell types. However, DX-52-1 treatment has been
shown to cause a disruption in the organization of actin cytoskeleton in DX-52-1-sensitive
cells such as T47D and MDA-MB-435, but not in non-sensitive cells such as Du145 siluc
and 4T07. Six DX-52-1 analogs were synthesized and structure-activity relationship (SAR)
studies were carried out in cell migration and in vitro competitive binding assays. We
provide strong evidence that the mechanism of covalent modification of galectin-3
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involves elimination of the nitrile group of DX-52-1 followed by an attack of a
nucleophilic amino acid side chain of galectin-3 on the resulting iminium ion. We propose
the similar mechanism for alkylation of radixin by DX-52-1. Furthermore, we
demonstrated that the hydroxyl group (-OH) of DX-52-1(C-19) plays an important role in
recognition of DX-52-1 and target proteins.

Introduction
The motility of cells is fundamental biological process that is relevant to finding food or
mating in simple organisms and crucial processes in embryonic development, tissue repair,
immune response, inflammation and angiogenesis in mammals [1,2], moreover, cell
migration also plays important role in cancer cell invasion and metastasis [3,4]. Small
molecules, that show anti-migratory activity in cancer cells can potentially prevent
metastasis, hold a great promise for important therapeutic approach. For instance,
approximate10-20% of breast cancers are found to be triple-negative, negative for estrogen
receptors (ER), progesterone receptors (PR), and HER2 (HER2), which means that the
growth of the cancer is not supported by the hormones estrogen and progesterone, nor by
the presence of too many HER2 receptors. Therefore, triple-negative breast cancer is
unable to be sufficiently treated by hormonal therapy (such as tamoxifen or aromatase
inhibitors) or therapies that target HER2 receptors, such as Herceptin. For many
researchers, there is an intense interest in discovering new drugs that can treat such breast
cancer [5-10]. Anti-migratory agents such as DX-52-1 have shown the great potential to
provide remedy for these kinds of problems.
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We have previously reported that two tetrahydroisoquinoline natural product analogs DX52-1 and HUK-921 showed anti-migratory activity in Madin-Darby canine kidney
epithelial cells with nanomolar and low micromolar concentrations, respectively. Two
protein targets involved in cell migration, the membrane cytoskeleton linker protein
radixin and the carbohydrate binding protein galectin-3, were identified as a primary and a
secondary target of DX-52-1 [11, 12]. We discovered radixin as a primary target of DX52-1 by employing a biotinylated derivative of DX-52-1 to pull down and purify target
proteins from MDCK whole cell lysates followed by a gel-based MS method [12]. DX-521 binds to the C-terminal domain of radixin specifically and covalently, causing the
dissociation of radixin, which is a linker protein between the membrane and actin, from
actin and other certain membrane proteins such as CD44, a cell adhesion protein and a
receptor for hyaluronic acid [12]. One of the three secondary targets of DX-52-1 we have
identified is galectin-3 [11]. This protein is a member of a family of carbohydrate-binding
lectins (for reviews, see refs. [13-15]). Galectin-3 contains a collagen-like domain in Nterminus that is rich in proline, glycine and tyrosine and a conserved C-terminal
carbohydrate recognition domain that carries out many important functions in cellular
processes. Galectin-3 is found in the nucleus and cytoplasm as well as in the extracellular
matrix where it is involved in cell-extracellular matrix (ECM) adhesion, cell-cell adhesion,
cell motility, cell differentiation, cell growth, cell proliferation, apoptosis and pre-mRNA
splicing (for reviews, see refs. [15-21]). Galectin-3 has been implicated in numerous
normal and disease processes, including inflammation, kidney development, angiogenesis,
heart failure and cancer progression and metastasis (for reviews, see refs. [17, 18, 22-27]).
Previously, we provided evidences to prove that galectin-3 is involved in cell migration in
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MDCK cells and, along with radixin galectin-3 is one of the targets of the anti-migratory
activity for DX-52-1. However, binding of DX-52-1 to galectin-3 shows little competition
with binding of β-galactosides, N-acetyllactosamine (LacNAc) or lactose [11]. Hence, we
considered that DX-52-1 binds outside of the carbohydrate-binding site of galectin-3,
unlike all the other known inhibitors of galectin-3 (for reviews, see refs. [28, 29]).
DX-52-1 partially reverses the morphology of galectin-3-overexpressing MDCK cells,
restoring the cells to more normal epithelial state [11]. DX-52-1 therefore represents a
potentially useful probe for evaluating the distinct contributions of galectin-3’s noncarbohydrate-binding functions to cell motility, cell adhesion and cell spreading.
Hence, two tetrahydroisoquinoline natural product analogs DX-52-1 and HUK-921 that
have promising anti-migratory activity in MDCK cells were used as powerful probes to
investigate the effects on different cancer cells in order to improve our understanding of
cancers and find possible potential drugs for cancer treatment. Therein, we investigated the
effects of the inhibitors on varied types of cancer cell lines including human breast cancer,
human prostate cancer, human melanoma and mouse breast cancer cells. We discovered
that DX-52-1 has promising anti-migratory activity and anti proliferation activity in T47D,
MDA-MB-435 and BT-20 cells (nanomolar concentration) and MDA-MB-231, 4T1, B16F10 and B16-BL6 cells ( low micromolar concentration). HUK-921 showed less potency
in comparison to DX-52-1. Further studies on the total target proteins expression and the
localization of the target proteins using immune blotting and immune fluorescence
microscopy suggest that DX-52-1 has no effect on neither case in cancer cells, meanwhile,
it has effects on the organization of the actin cytoskeleton in the drug-sensitive cells such
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as T47D and MDA-MB-435, but not in the non-sensitive cells such as Du145 siluc and
4T07.
SAR studies of small molecules allow us to determine which component of the molecule is
most crucial to its biological activity [30]. In this study, six different analogs of DX-52-1
were synthesized. Quantitative wound closure assays were carried out in the human breast
cancer MDA-MB-435 cells along with competitive binding assays with radixin and
galectin-3 in the presence of biotinylated DX-52-1. Herein, we found that the hydroxyl
group (OH) has an important impact on DX-52-1 to recognize the target proteins in vitro
and in vivo. We provide strong evidence that the mechanism of covalent modification of
galectin-3 involves elimination of the nitrile group of DX-52-1 followed by the attack of a
nucleophilic amino acid side chain of galectin-3 on the resulting iminium ion. The similar
mechanism is proposed for alkylation of radixin.

Materials and methods
Cell culture
MDA-MB-231, MDA-MB-435, T47D, 4T1, 4T07, MCF7, B16-BL6, B16-F10, and Du145
siluc cells were cultured in a growth medium containing D-MEM (Dulbecco's Modified
Eagle Medium) and 10% FBS (Fetal Bovine Serum), BT20 cells were cultured in a growth
medium of MEM (Minimum Essential Medium) with 10% FBS (Fetal Bovine Serum),
168FARN cells were cultured in a growth media consisting of D-MEM (Dulbecco's
Modified Eagle Medium) with 5% FBS (Fetal Bovine Serum) and 5% of NCS (Newborn
Calf Serum) and grown at 37 °C with 5% CO2 in a humidified tissue culture incubator.
Early passages of cells cultured from frozen stock cultures were used in all experiments.
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Main cultures were grown in 75-cm2 tissue culture flasks with medium changed every two
days. When the cultures reached 90% confluence, the cells were gently washed twice with
phosphate

buffered

saline

(PBS),

and

treated

with

a

solution

of

trypsin/

ethylenediaminetetraacetic acid (EDTA) in PBS to detach cells from the flasks. After cells
were detached, an equal volume of fresh medium was added to inhibit the trypsin activity.
The cells were resuspended in media and cell density was determined with a
hemacytometer. Cells were replanted in fresh medium in new tissue culture flasks for
continued culture and multi-well tissue culture plate for experiments.
Wound closure assay
The qualitative wound closure assays were carried out prior to the quantitative ones in
order

to

identify

those

cancer

cell

lines

that

have

positive

response

to

tetrahydroisoquinoline natural product analogs DX-52-1 and HUK-921. In both qualitative
and quantitative assays, confluent cell monolayers of selected cell lines were treated with
compounds at various concentrations in cell culture medium. Wounds in the monolayers
were made using the sterile plastic micropipette tips after incubation at 37°C for 30
minutes. Pictures were taken every three hours until the control closed by the time of postwounding and were then imported into ImageJ for morphometric analyses. Toxicity was
determined at the end of experiments via the Trypan blue dye exclusion assay.
Cell proliferation assay
Cancer cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). The
media was changed after 24 hrs with media containing varies concentrations of DX-52-1 or
HUK-921. After another 48hrs, cell numbers were counted with Cell Counting Kit-8
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(Dojindo), a tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax
Plus384, Molecular devices) based on manufacturer's protocol.
Expression and purification of recombinant galectin-3 and radixin
Glutathione S-transferase (GST) fusion with full length human galectin-3 and mouse
radixin in the pGEX-2T vector were expressed in BL21 (DE3) Escherichia coli cells.
Small amount of glycerol stock was picked to seed cultures in 10 mL of Luria-Bertani
medium with adding 50 µg/ mL ampicillin. After growing the cells overnight at 37°C, the
culture was transferred to 500 mL autoclaved LB medium then ampicillin was added to a
final concentration of 50 µg/ mL, followed by incubation until the OD600 was between 0.6
~ 0.9. Then, a final concentration of 1 mM IPTG was added and followed by incubation at
37°C for 4 hours. The cells were then harvested by centrifugation (5,000 rpm for 10 min.).
The pellets were resuspended in 10 mL ice-cold PBS containing 2 mM EDTA, 0.5%
Trixton X-100, 100 µg/mL lysozyme, 2 mM DTT (dithiothreitol), 1 µg/mL leupeptin, 1
µg/mL pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 0.1 mM benzamidine
on ice for 30 minutes. The homogenized lysates were centrifuged at 15,000 rpm for
30 minutes at 4°C. The supernatants were collected and then mixed with 500 µL of
glutathione agarose beads and rotated overnight at 4°C. Beads were washed three times
with PBS and collected by centrifugation at 5,000 rpm for 10 minutes at 4°C. Thrombin
(10 units) was added to the solution and incubated overnight at 4°C and protein solution
was collected and the protein concentration was determined by the UV spectrum. Each
recombinant protein was ultimately used in a buffer containing 20 mM Tris-HCl (pH 7.4),
150 mM NaCl, 2 mM EDTA, 2mM DTT, 0.5% (w/v) Triton X-100, 1 µg/mL leupeptin, 1
µg/mL pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride, and 0.1 mM benzamidine.
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Competitive DX-52-1 analogs binding assays
Recombinant full length galectin-3 and radixin were tested under the same conditions. For
each sample, 20 µM protein (full length galectin-3 or full length radixin) in a buffer
containing 20 mM Tris, pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM DTT, 1 µg/mL
leupeptin, 1 µg/mL pepstatin A, 100 µM PMSF and 100 µM benzamidine with 10 µM
biotinylated DX-52-1and 50- fold molar excess of free DX-52-1 or DX-52-1analogs.
Samples were incubated at 4°C for 16 hours, then an equal volume of 2xSDS sample
buffer was added to each sample, separated by SDS-polyacrylamide gel electrophoresis,
transferred onto a polyvinylidene difluoride (PVDF) membrane, and blotted with an antibiotin antibody ( from Cell Signaling Biotechnology). The samples were detected
streptavidin-HRP (Sigma) and chemiluminescence (GE health).

Immunoblot Analysis
Confluent cancer cells grown in 100-mm diameter tissue culture dishes were gently
washed twice with PBS, and then lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4,
150 mM NaCl, 2 mM ethylene diamine tetraacetic acid (EDTA), 0.5% Trixton-100, 2 mM
DTT, 1 µg/mL leupeptin, 1 µg/mL pepstatin A, 0.1 mM phenylmethylsulfonyl fluoride
(PMSF), 0.1 mM benzamidine and 100 µM sodium orthovanadate) on ice for 30 minutes.
The lysates were separated by centrifugation at 15,000rpm for 30 minutes at 4°C.
Supernatants were collected and the total protein concentration determined by the Bradford
assay.

All the lysates were

separated by SDS-polyacrylamide gel electrophoresis,

transferred onto a polyvinylidene difluoride (PVDF) membrane, and blotted with an anti-
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radixin antibody, anti-galectin-3 antibody and an anti-actin antibody (both from Santa Cruz
Biotechnology).

Fluorescence Microscopy
MDCK, T47D, MDA-MB-435 and 4T07 cells were plated onto glass coverslips placed in
12-well tissue culture plates and grown to confluence. DX-52-1 was added to the plates
and incubated at 37 °C in 5% CO2 overnight. To visualize galectin-3 localization, cells
were fixed with 3.7% formaldehyde in PBS for 15 minutes and permeabilized with 0.5%
Triton X-100 for 15 minutes. The cells were then immunostained with a mouse antigalectin-3 monoclonal antibody (Santa Cruz Biotechnology.) and an Alexa Fluor 350conjugated goat anti-mouse IgG secondary antibody (Invitrogen/Molecular Probes). 10 µL
of 10 µg/mL 4'6-diamidino-2-phenylindole (DAPI, Sigma) was placed on each cover slide
to stain the nuclei of cells. The cover slides were then mounted to glass slides. T47D,
MDA-MB-435, 4T07 and Du145 siluc cells were stained for F-actin with 50 nM
tetramethylrhodamine isothiocyanate (TRITC)-labeled phalloidin (Sigma). The cover
slides were mounted onto glass slides in Mowiol 4-88 (0.1 g/ml) mounting medium
(Calbiochem) containing 15 mg/mL antifade agent 1, 4-diazabicyclo [2, 2, 2] octane
(Sigma). The slides were examined on an inverted fluorescence microscope (Leica DMI
6000B), and images were captured using a Hamamatsu Orca AG cooled charge-coupled
device camera.

Nuclei/ cytoplasm ratio of galectin-3 localization
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Nuclei/ cytoplasm ratio of galectin-3 localization was calculated by the software (Velocity
software. Inc)

Results

Tetrahydroisoquinoline Natural Product Analogs DX-52-1 and HUK-921 Showed
Anti-migratory Activity in Different Cancer Cell Lines
We first investigated the effects of two tetrahydroisoquinoline natural product analogs DX52-1 and HUK-921 on the cell sheet migration of eleven different cancer cell lines
including MDA-MB-231, MDA-MB-435, T47D, 4T07, MCF7, B16-BL6, BT-20, 4T1,
168FARN, B16-F10, and Du145 siluc. Cell migration was inhibited by both compounds in
a dose-dependent manner.
Moreover, minimum inhibitory concentration (MIC), minimum lethal concentration
(MLC), IC50 for inhibition of cell migration and maximum percent of subtoxic inhibition
were determined to evaluate the potency and selectivity of the two compounds on the
cancer cell lines as shown (Tables 1 and 2). DX-52-1 inhibited cell migration on MDAMB-231, MDA-MB-435, BT-20, T47D, 4T1, B16-BL6 and B16-F10 cells. HUK-921
showed anti-migratory activity on MDA-MB-435, BT-20, T47D, B16-F10 and 168 FARN
cells. Among all the tested cell lines, the maximum percent of subtoxic inhibition of DX52-1 of the drug-sensitive cell lines varied from 67% (MDA-MB-435) to 32% (MDA-MB231and 4T1). While for HUK-921, it varied from 49% (T47D) to 28% (MDA-MB-435).
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Table 1. Effect of DX-52-1 on the Migration of Different Cancer Cell Lines
IC50 for
inhibition of
cell migration
(at indicated
time postwounding)b
213 nM (24
h)

Cell line

Minimum
inhibitory
concentrationa

MDAMB-435

50 nM

B16-BL6

3 µM

4.7 µM (12 h)

B16-F10

6 µM

7.7 µM (12 h)

MDAMB-231

25 µM

BT-20

500 nM

T47D

40 nM

MCF7
4T1
4T07
168FARN
DU145
a

57.4 µM (24
h)
687 nM (24
h)
52.3 nM (36
h)

95%
confidence
interval for
IC50
136 nM–
332 nM
3.7 µM–5.9
µM
4.3 µM–
13.8 µM
19.7 µM–
167.2 µM
500 nM–
944 nM
41.2 nM–
66.4 nM

Maximum
percent of
subtoxic
inhibitionc
67% (500
nM)
66% (10
µM)
42% (12
µM)
32% (200
µM)
37% (25
µM)
50% (100
nM)

No subtoxic
activity

NAe

NAe

NAe

250 nM

1 µM

30.7 µM (12
h)

9.8 µM–
95.9 µM

32% (50
µM)

100 µM

NAe

NAe

NAe

100 µM

NAe

NAe

NAe

500 µM

NAe

NAe

NAe

500 nM

No subtoxic
activity
No subtoxic
activity
No subtoxic
activity

Minimum
lethal
concentrationd
600 nM
15 µM
15 µM
500 µM
50 µM
250 nM

Minimum inhibitory concentration defined as the lowest concentration at which there was

a statistically significant decrease in the mean rate of migration in the wound closure assay
compared to parallel controls from three independent experiments for each compound.
b

Half-maximal concentration for inhibition of cell migration, as determined by

quantitation of the degree of wound closure at the parenthetically indicated times postwounding compared to parallel controls for a range of concentrations.
c

Percent inhibition of wound closure at the highest subtoxic concentration (indicated in

parentheses), measured for the same time post-wounding for each compound as the IC50.
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The higher the percentage, the more inhibitory the compound is relative to parallel
controls.
d

Minimum lethal concentration defined as the lowest concentration at which there was

evidence of cytotoxicity based on the trypan blue dye exclusion assay conducted at the
end of each experiment.
e

Not applicable.

DX-52-1 had a promising drug like dose-dependent inhibitory profile, in which a
statistically significant minimum inhibitory concentration of 50 nM (unpaired two-tailed
Student’s t-test for percent wound closure at 24 h for 50 nM DX-52-1 vs. 0.01% dimethyl
sulfoxide (DMSO) carrier solvent control for data in Table 1.) and a minimum lethal
concentration of 600 nM on MDA-MB-435, a melanoma cell line, was observed. Also,
DX-52-1 had an effect on two triple negative breast cancer cell lines BT-20(MIC 500 nM)
and MDA-MB-231 (MIC 25 µM), a metastatic breast cancer cell line 4T1 (MIC 1 µM) and
a human ductal breast epithelial tumor cell line T47D (MIC 40 nM). Furthermore, two
melanoma cell lines B16-BL6 and B16-F10 showed sensitivity to DX-52-1 with the MIC
value of 3 µM and 6 µM, respectively. HUK-921 showed different effects on migration of
different cancer cell lines. As seen in Table 2, HUK-921
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Cell line

Minimum
inhibitory
concentrationa

IC50 for
inhibition of
cell migration
(at indicated
time postwounding)b

MDAMB-435

10 µM

24.4 µM (24
h)

B16-BL6

No subtoxic
activity

B16-F10

95%
confidence
interval for
IC50
3.5 × 1013–1.7 ×
103 µM

Maximum
percent of
subtoxic
inhibitionc

Minimum
lethal
concentrationd

28% (50
µM)

100 µM

NAe

NAe

NAe

5 µM

500 nM

19.6 µM (24
h)

12.3 µM–
31.2 µM

48.7 % (25
µM)

50 µM

MDAMB-231

No subtoxic
activity

NAe

NAe

NAe

50 µM

BT-20

25 µM

NDf

NAe

NAe

50 µM

T47D

25 µM

44.5 µM (36
h)

21.3 µM–
91.3 µM

49% (50
µM)

100 µM

NAe

NAe

NAe

50 µM

NAe

NAe

NAe

200 µM

NAe

NAe

NAe

100 µM

MCF7
4T1
4T07

No subtoxic
activity
No subtoxic
activity
No subtoxic
activity

168FARN

25 µM

43.5 µM (48
h)

35.7 µM–
52.9 µM

45% (50
µM)

100 µM

DU145

No subtoxic
activity

NAe

NAe

NAe

25 µM

Table 2. Effect of HUK-921 on the Migration of Different Cancer Cell Lines
a

Minimum inhibitory concentration defined as the lowest concentration at which there was

a statistically significant decrease in the mean rate of migration in the wound closure assay
compared to parallel controls from three independent experiments for each compound.
b

Half-maximal concentration for inhibition of cell migration, as determined by

quantitation of the degree of wound closure at the parenthetically indicated times postwounding compared to parallel controls for a range of concentrations.
c Percent inhibition of wound closure at the highest subtoxic concentration (indicated in
parentheses), measured for the same time post-wounding for each compound as the IC50.
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The higher the percentage, the more inhibitory the compound is relative to parallel
controls.
d Minimum lethal concentration defined as the lowest concentration at which there was
evidence of cytotoxicity based on the trypan blue dye exclusion assay conducted at the end
of each experiment.
e Not applicable.
f Not determinable because of extremely narrow concentration-response range.
has effects on two melanoma cell lines MDA-MB-435 (MIC 10 µM) and B16-F10 (MIC
500 nM), a human ductal breast epithelial tumor cell line T47D (MIC 25 µM) and a nonmetastic breast cancer cell line 168FARN (MIC 25 µM).

Tetrahydroisoquinoline Natural Product Analogs DX-52-1 and HUK-92-1 Showed
Anti-proliferation Activity in Different Cancer Cell Lines
We investigated the effects of DX-52-1 and HUK-921 on the proliferation of the
aforementioned several cancer cell lines. Cell proliferation was inhibited by both inhibitors
in a dose-dependent manner. Moreover, minimum inhibitory concentration (MIC),
minimum lethal concentration (MLC) and IC50 value for inhibition of cell proliferation
were obtained to evaluate the potency and selectivity of the two inhibitors of the tested cell
lines as shown (Table 3 and 4). All the tested cell lines showed sensitivity to DX-52-1
treatment, as seen in Table 3, MDA-MB-231, MDA-MB-435, MCF7, and T47D showed
the highest sensitivity with a MIC at 100 nM and BT-20 (MIC 1 µM), 4T07 (MIC 1 µM)
and 168FARN (MIC 1 µM) showed the least sensitivity to DX-52-1 treatment. HUK-921
also showed anti-proliferation activity in a dose-dependent manner in some cell lines, as
shown in Table 4. MCF7 (MIC 500 nM) showed the highest sensitivity. 4T1 (MIC 25
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µM), MDA-MB-435(MIC 25 µM) and 168FARN (MIC 25 µM) showed the least
sensitivity to HUK-921 treatment. Similar to inhibition of cell migration,

Table 3. Effect of DX-52-1 on the Proliferation of Different Cancer Cell Lines

Minimum
inhibitory
concentrationa

95%
Minimum
confidence
lethal
interval for
concentrationc
IC50
MDA142 nM–187
100 nM
163 nM
1 µM
MB-435
nM
1.0 µM–2.0
B16-BL6
500 nM
5 µM
1.4 µM
µM
1.2 µM–1.8
B16-F10
500 nM
5 µM
1.5 µM
µM
MDA71 nM–397
100 nM
179 nM
5 µM
MB-231
nM
1.2 µM–1.6
BT-20
100 µM
1 µM
1.4 µM
µM
213 nM–245
T47D
100 nM
228 nM
500 nM
nM
159 nM–195
MCF7
100 nM
176 nM
500 nM
nM
535 nM–902
4T1
500 nM
695 nM
10 µM
nM
1.7 µM–3.0
4T07
10 µM
1 µM
2.2 µM
µM
1.73 µM–2.24
1 mM
168FARN
1 µM
1.96 µM
µM
254 nM–387
DU145
250 nM
314 nM
500 nM
nM
a
Minimum inhibitory concentration, defined as the lowest concentration at which there
Cell line

IC50 for inhibition of cell
proliferationb

was a statistically significant reduction in mean cell number at 48 h relative to control cells
at 48 h from three independent experiments in a tetrazolium salt-based assay.
b

Half-maximal concentration for inhibition of cell proliferation, calculated from mean cell

numbers at 48 h for a range of concentrations.
c

Minimum lethal concentration, defined as the lowest concentration at which there was a

statistically significant reduction in mean cell number after 48 h from the mean number at
48

0h (initial cell number). Note: cells are at a lower density in this assay than in the wound
closure assay.
inhibition of cell proliferation by DX-52-1 and HUK-921 showed a wide variety of
sensitivity across the cancer cell lines tested.
Table 4. Effect of HUK-921 on the Proliferation of Different Cancer Cell Lines

Cell line

Minimum
inhibitory
concentrationa

IC50 for inhibition of cell
proliferationb

95%
confidence
interval for
IC50

Minimum
lethal
concentrationc

MDAMB-435

No subtoxic
activity

NAd

NAd

100 µM

B16-BL6

1 µM
No subtoxic
activity

2.0 µM

1.5–2.7 µM

5 µM

NAd

NAd

50 µM

MDAMB-231

25 µM

27.3 µM

BT-20

5 µM

7.1 µM

T47D

No subtoxic
activity

NAd

MCF7

500 nM

10.8 µM

4T1

25 µM

35.0 µM

4T07

No subtoxic
activity

NAd

NAd

25 µM

168FARN

25 µM

32.9 µM

31.3 µM–34.6
µM

100 µM

B16-F10

13.3 µM–55.6
µM
6.9 µM–7.3
µM
NAd
9.3 µM–12.7
µM
27.3 µM–44.9
µM

50 µM
25 µM
25 µM
50 µM
50 µM

No subtoxic
NAd
NAd
25 µM
activity
Minimum inhibitory concentration, defined as the lowest concentration at which there

DU145
a

was a statistically significant reduction in mean cell number at 48 h relative to control cells
at 48 h from three independent experiments in a tetrazolium salt-based assay.
b

Half-maximal concentration for inhibition of cell proliferation, calculated from mean cell

numbers at 48 h for a range of concentrations.
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c

Minimum lethal concentration, defined as the lowest concentration at which there was a

statistically significant reduction in mean cell number after 48 h from the mean number at
0 h (initial cell number). Note: cells are at a lower density in this assay than in the wound
closure assay.
d

Not applicable.

Total Protein Expression of Radixin and Galectin-3 in Different Cancer Cell Lines
Since different cell lines showed different response to the treatment of DX-52-1 or HUK921 in cell migration and cell proliferation assays, and with the knowledge that DX-52-1
targets both radixin and galectin-3 whereas HUK-921 targets galectin-3, we investigated
the total expression level of both target proteins in all tested cancer cell lines in order to
correlate the anti-migratory activity of the two small molecule inhibitors on different cell
lines with either galectin-3 or radixin. As shown in Table 5, radixin is expressed in all cell
lines except 168FARN but galectin-3 is expressed in T47D, MCF7, MDA-MB-435, MDAMB-231 and BT20 cells.
MD

T47D

CK

MCF

4T07

7

168

MDA-

BT

B16-

MDA-

FARN

MB-435

20

BL6

MB-

4T1

B16-

Du

F10

145

231

siluc

Rad

+

+

+

+

_

+

+

+

+

+

+

+

Gal-3

+

+

+

_

_

+

+

_

+

_

_

_

DX

+

+

_

_

_

+

+

+

+

+

+

_

HUK

+

+

_

_

+

+

_

_

_

_

+

_

Table 5. The Expression of Radixin or Galectin-3 in Different Cell Lines
All cell cultures were incubated at 37°C in 5% CO2 until more than 90% confluent. Cells were
lysed after washed twice by PBS and the total protein concentration was measured by Bradford
assays and then subjected to SDS-PAGE with the same amount. Galectin-3 or radixin was probed
by antibody in each case. Results were obtained by the means of more than three individual
experiments.
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Among all the cell lines that express both radixin and galectin
galectin-3,
3, MDCK, T47D, MDA-MB-435
MDA
cells were sensitive to both of the inhibitors.

Tetrahydroisoquinoline
uinoline Natural Product Analog DX-52-1
1 Does Not Result in
Degradation of Galectin-33 or Radixin in C
Cells
We investigated the effect of DX
DX-52-1
1 on the overall expression level of radixin and
galectin-3,
3, a primary and secondary target protein of DX
DX-52-1,
1, in MDCK and T47D cells.
The results of the immunoblot analysis (Figure 1) suggested that DX-52--1 does not result
in degradation of galectin-33 or radixin in cells.

A

B

C

Figure 1. DX-52-11 Does Not Result in Degradation of Galectin
Galectin-3
3 or Radixin in Cells
DX-52-11 does not result in degradation of galectin
galectin-3
3 or radixin in MDCK or T47D cells.
MDCK and T47D cell cultures were incubated at 37°C in 5% CO2 until more than 90%
confluent. Cells were lysed after treatment with 500nM DX
DX-52-1
1 for 12 hours, and
whole-cell
cell extracts were subjected to SDS
SDS-PAGE.
PAGE. Intensity of bands from samples in the
absence or presence DX
DX-52-1 was calculated and analyzed by Image J software. Results
were obtained by the means of more than three individual experiments. (A) Galectin-3
Galectin
was probed from T47D whole cell lysate in the absence or presence of DX-52-1;
DX
(B)
Galectin-33 was probed from MDCK whole cell lysate in the absence or presence
pre
of DX52-1;
1; (C) Radixin was probed from T47D (left) and MDCK (right) whole cell lysate in
the absence or presence of DX
DX-52-1.
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DX-52-1 Does Not Affect the Localization of Galectin-3
3 in Cells but Disrupts the
Organization of the Actin C
Cytoskeleton in Drug-sensitive
sensitive Cancer Cells
It is known that the cytoplasmic versus nuclear expression
pression of galectin-3
galectin in vivo is
associated with cancer cell invasion and metastasis [31
[31-36].
36]. Based on the fact that DX-521 does not result in degradation of galectin
galectin-3 in cells, more information is needed to
understand how DX-52-11 interacts with galectin
galectin-3
3 in cells and inhibits the cell migration in
cancer cell lines> We investigated the localization of galectin
galectin-3
3 and the organization of the
actin cytoskeleton in different types of cells in the absence or presence of DX-52-1.
DX
With
the consideration of variety of samples, both drug
drug-sensitive
sensitive cell lines such as MDCK (Fig.
2A), T47D (Fig. 2B) and MDA
MDA-MB-435(Fig. 2C) and non-sensitive
sensitive cell line such as 4T07
(Fig. 2D) were investigated
igated for the localization of galectin
galectin-3
3 in both nucleus and
cytoplasm. Based on the nuclei/ cytoplasm ratio of galectin
galectin-3,
3, we found that there is no
significant difference on localization of galectin
galectin-3
3 in all four cell lines regardless of
whether or not they are drug
drug-sensitive (Fig. 2E).

A
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B

C

D

53

E

Figure 2. The Treatment of DX
DX-52-1
1 Does Not Affect the Localization of Galectin-3
Galectin
(A), (B), (C) and (D) are images showing MDCK, T47D, MDA
MDA-MB-435
435 and 4T07 cells stained by
DAPI for nucleus and probed by a secondary fluorescence labeled antibody to detect a primary
anti-galectin-33 antibody. Confluent monolayers of cells were washed twice by PBS buffer and then
treated with carrier solvent DMSO as controls or DX
DX-52-1
1 of 500 nM for MDCK, 200 nM for
T47D, 500 nM for MDA-MB
MB-435 and 50 µM for 4T07,, 12 h later, fixed and processed for
imaging, as described in Experimental Procedures. Scale bar = 50 µm. (E) The nuclei/cytoplasm
ratio of galectin-33 expressed in MDCK, T47D, MDA
MDA-MB-435
435 and 4T07 cells in the absence or
presence of DX-52-1. The ratio was calculated using the software (Velocity software. Inc.).

DX-52-11 Treatment Causes a Disruption in the Organization of the Actin
Cytoskeleton in Drug-sensitive
sensitive Cell B
But Not in Non-sensitive Cells
More information is needed to fully explain the facts that DX
DX-52-1
1 shows different antianti
migratory activity in different cancer cell lines. By binding to eith
either
er radixin or galectin-3,
galectin
DX-52-11 has direct or indirect interaction with the actin network and inhibits cell
migration through the network. Therefore, we investigated the effect of DX-52-1
DX
in the
organization of the actin cytoskeleton in drug
drug-sensitive cell
ll lines, T47D and MDA-MBMDA
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435, and non-sensitive cell lines, 4T07 and Du 145 siluc, in the absence or presence of
DX-52-1 using immune fluorescence

A

B

Figure 3. DX-52-1 Treatment Causes a Disruption in the Organization of the
Actin Cytoskeleton in Drug-sensitive Cell Lines Such as T47D and MDA-MB-435
But Not the Non sensitive Cells Such as Du145 siluc and 4T07
(A) (B) are images showing T47D, MDA-MB-435, Du145 siluc and 4T07 cells stained for Factin with 50 nM tetramethylrhodamine isothiocyanate (TRITC)-labeled phalloidin (Sigma).
Confluent monolayers of cells were washed twice by PBS buffer and then treated with carrier
solvent DMSO as controls or DX-52-1 of 200 nM for T47D, 500 nM for MDA-MB-435, 50
µM for 4T07 and 400 nM for Du145 siluc, 12 h later, fixed and processed for imaging, as
described in Experimental Procedures. Scale bar = 50 µm.
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microscope. We found that DX-52-1 treatment causes a disruption in the organization of
the actin cytoskeleton in drug-sensitive cell lines, such as T47D and MDA-MB-435 (Fig.
3A ), but not in non-sensitive cell lines, such as 4T07 and Du 145 siluc (Fig. 3B). As seen
in the images (Fig. 3A top), the filopodia of MDA-MB-435 cells are very long and the
cells spread more without the inhibitor treatment, whereas the cells with compound
treatment are rounder and have very short filopodia. The lamellae in T47D cells also
showed difference in the absence or presence of DX-52-1 (Fig. 3A bottom). As seen in the
figure, the actin network in the untreated cells is well organized, fine and smooth,
thoroughly distributed across the cells while the network is not evenly spread in the treated
cells. This observation implies that the network is partially broken at the edge of cells and
more concentrated in the cytoplasm by the treating the compounds. Furthermore, as shown
in Fig. 3B, there is no difference for the actin cytoskeleton in DX-52-1 non-sensitive 4T07
and Du145 siluc cells with or without compound treatment, which is unlike in drugsensitive cell lines T47D and MDA-MB-435.

SAR Studies of DX-52-1 Suggests that Hydroxyl Group (OH at C19) is Crucial for
Target Identification
Six analogs of DX-52-1 were synthesized (shown in Fig. 4) and the structures were
confirmed by nuclear magnetic resonance (NMR) and mass spectrometry (MS). These
compounds were used in wound closure assays and competitive binding assays. Herein we
discovered that among these compounds DX-A-4 showed similar competitive binding
ability on both target proteins galectin-3 and radixin and similar anti-migratory activity on
MDA-MB-435 cancer cells. The rest of the analogs showed a partial or total loss of the
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ability to compete with biotinylated DX-52-1 binding to the two target proteins.
Furthermore, a loss of anti-migratory activity on MDA-MB-435 cancer cells was also
observed (Table 6.). Thus, we believe that the nitrile group is responsible for the inhibitors
binding to the target proteins in vivo and in vitro and the hydroxyl group plays an
important role in recognition by target proteins can be supported.

Discussion
The identification of radixin and galectin-3 as the target proteins of DX-52-1 in the process
of cell migration gives an opportunity to define the roles of these two proteins in cell
motility and other important biological processes, which also holds the promise of a
potential cancer therapy. Furthermore, the compound HUK-921, which shares structural
similarity with DX-52-1 also showed anti-migratory activity in MDCK cells. The fact that
DX-52-1 and HUK-921 inhibit cell migration [11] and bind to galectin-3 outside of its
carbohydrate-binding site of galectin-3 indicates that these compounds also inhibit other
galectin-3 functions that may also be important in cell migration. Furthermore, since
LacNAc does not inhibit migration of MDCK cells, the function(s) of galectin-3 involved
in cell motility in this system appear independent of its β-galactoside-binding activity. In
addition, while less potent than DX-52-1, the remarkable selectivity of HUK-921 for
galectin-3 over radixin suggests that target selectivity derives from specific recognition
interactions between protein and small molecule prior to alkylation. Therefore further
development of structurally related molecules would yield compounds with yet different
selectivities, such as those with greater selectivity for radixin over galectin-3. Because of
galectin-3’s multiple roles in cancer pathogenesis, proliferation, and spreading of
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Table 6. Structure-activity Relationship Study of DX-52-1 and Its Analogs

Compound

R1

R2

R3

R4

R5

IC50/Activity

Binding ability

DX-52-1

-CN

-OH

-OCH3

-H

-COOH

213 nM

Rad, 100%; Gal-3,100%

DX-A-1

-H

-OH

-OCH3

-H

-COOH

NA

Rad, 22.22±12.66%;
Gal-3, 3.76±4.08

DX-A-2 -C≡C-H/TMS -OH

-OCH3

-H

-COOH

NA

Rad, 16.51±6.36%
Gal-3, 4.51±1.31%

DX-A-3

-H

-OCH3

-H

-CH2OH

NA

Rad, 22.84±14.56%
Gal-3, 3.51±1.10%

DX-A-4

-CN

-Br

-COOH

218 nM

Rad, 133.1±81%
Gal-3, 72.6±48.9%

DX-A-5

-CN

-OOCCH3 -OCH3

-H

-COOH

NA

Rad, 52.5±1.15%
Gal-3, 47.7±28.6%

DX-A-6

-CN

-OOCCH3 -OCH3

-Br

-COOH

NA

Rad, 25.6±8.16%
Gal-3, 35.7±1.88%

-OH

-OH

-OCH3

Note: Normalized Relative Competition Equation

Unlike a percentage simply based on DX-52-1 Band/Analog Band ratio, the above
formula returns a value of 0% if the analog band is equal to control band (no competition)
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and 100% if analog band is equal to DX-52-1 band (competition unaffected). All IC50
values were calculated for inhibition of wound closure at the indicated times postwounding with normalization to parallel controls by using five different subtoxic
concentrations in concentration-response experiments. Each concentration for MDA-MB435 cancer cells assay involved at least three separate experiments and was considered a
bioactive concentration if there was statistically significant inhibition with ρ < 0.05 by an
unpaired two-tailed Student’s t test.
metastasis, there is considerable interest in the development of new galectin-3 inhibitors.
Existing galectin-3 inhibitors are carbohydrate or peptide-based which target the
carbohydrate-binding site of the protein’s C-terminal carbohydrate-recognition domain (for
reviews, see Refs. [28,29]). DX-52-1 and HUK-921 are thus unique in that they
specifically bind galectin-3 outside of its carbohydrate-binding site. Thus, it is worth
investigating when they are used as powerful probes to study the effects on different cancer
cells in the processes of cell migration and cell proliferation.
It is very interesting that DX-52-1 and HUK-921 showed different anti-migratory activity
and anti-proliferation ability on the eleven different cancer cell lines that cover a large
range of cancer types. This finding indicates that the two small molecule inhibitors are
more specific to certain type of cancers than others. Furthermore, the selectivity of a
compound is crucial to higher efficacy and lower side effects. Results shown in Table 1-4
exhibit that DX-52-1 has a promising drug like dose-dependent inhibitory profile on
MDA-MB-231, MDA-MB-435, BT-20, T47D, 4T1, B16-BL6, B16-F10 cells, which also
could be true for HUK-921 in terms of anti-migratory activity on MDA-MB-435, BT-20,
T47D, B16-F10 and 168 FARN cells. Although HUK-921 showed far greater selectivity
on galectin-3 over radixin, HUK-921 acted largely differently on tested cancer cells in the
process of cell migration. Therefore we tried to answer the question that do these two
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inhibitors act differently in terms of cell migration and cell proliferation because of the
different selectivity they showed on the two target proteins radixin and galectin-3? If so,
can we correlate the selectivity of the inhibitors with the expression level of the two target
proteins? In order to uncover the information behind, we investigated the overall cellular
expression of the two proteins on all the tested cell lines and tried to find the correlation
between them. As seen in Table 5, radixin is expressed in all tested cell lines except
168FARN and galectin-3 is expressed in T47D, MCF7, MDA-MB-435, MDA-MB-231
and BT20 cells. Both of the compounds, DX-52-1 and HUK-921, showed inhibition on
MDCK, T47D, MDA-MB-345 and B16-F10 cells. Unfortunately, the relation between the
selectivity of the two inhibitors and the protein expression level is more miscellaneous than
being straightforward or simply connected, which implies that the living cell is a much
more complicated system rather than being a model to do biological assays with. For
instance, both DX-52-1 and HUK-921 showed anti-migratory activity on MDCK, T47D,
MDA-MB-345 and B16-F10 cells in which both radixin and galectin-3 are expressed in the
first three cell lines but not in B16-F10 cells. Surprisingly, neither DX-52-1 nor HUK-921
showed inhibition on MCF7 cells even though both target proteins are expressed in this
cell line. HUK-921 inhibits cell migration in 168FARN cells which indicates that the
compound targets some other protein(s) besides galectin-3 involved in cell motility since
neither radixin or galectin-3 is expressed in 168FARN cells. In addition, HUK-921 also
shows anti-migratory activity in B16-F10 cells in which galectin-3 expression is not
detected by immune blotting assays. Since, it is hard to derive a direct correlation from the
information obtained based on the overall cellular expression of the two target proteins and
the selectivity of the two inhibitors, further studies are needed to aid in better
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understanding on how the small molecule inhibitors work in cells and how we can develop
a better inhibitor with higher selectivity and potency. Based on the results we obtained
from investigating eleven cancer cell lines, it is most likely that HUK-921 targets other
proteins involved in cell motility besides galectin-3 in living cells. In addition the “big”
size of HUK-921 in consideration of Lipinski's Rule of Five makes it a less potential drug
to be pursued in further studies
Previously we learned that the sensitivity of MDCK cells to DX-52-1’s anti-migratory
activity is reduced when either radixin [12] or galectin-3 is overexpressed [11]. This is
most likely due to the fact that both of the proteins are specific DX-52-1 binding proteins;
overexpression of either protein effectively “titrates” out a large proportion of the soluble
DX-52-1, reducing its concentration in cells and thus its ability to inhibit either protein
completely. Binding of small molecule inhibitors to the target proteins often causes
conformational changes of the complexes, which leads to degradation of the proteins as the
cutting sites of the proteins may be “exposed” to the proteases. Does such thing happen
during binding of DX-52-1 to radixin or galectin-3 in the living cells? That is a very
interesting question to be asked here because changes were observed when DX-52-1 was
used to treat cells in the process of cell migration. Therefore further investigation will be
very helpful for understanding how DX-52-1 works with radixin or galectin-3 in living
cells.
Unlike radixin, galectin-3 is ubiquitously expressed in cells and can be found in the
cytoplasm, nucleus and extracellular matrix [37, 38]. The dynamics of galectin-3’s roles in
the cytoplasm and nucleus have yet to be determined. For instance, galectin-3 undergoes
post-translational modification, phosphorylation of a serine residue by the protein kinase

61

casein kinase 1 (CK1), which triggers the signals to export galtecin-3 to the cytoplasm thus
can function as a molecular switch to activate the carbohydrate binding ability [39-42]. In
addition, the nuclear localization of galectin-3 is perhaps relevant to cell proliferation
because it plays an essential role in the process of splicing pre-mRNA [43]. In cancer cells,
galectin-3 also plays a significant role in tumor progression [44–49]. In some cancers,
galectin-3 shows up-regulation on growth by inducing cyclin D1 and c-Myc in the nucleus
of human breast cancer [44-46]. Moreover, the cytoplasmic/nuclear expression ratio of
galectin-3 is associated with tumor invasion and metastasis in vivo [31-36]. In many cases,
the level of nuclear galectin-3 expression is reported largely different in cancer cells [3133] compared to normal cells and can be used as a predictive factor and a crucial
pathological parameter [34-36].
The data presented here (Fig.1) show that DX-52-1 does not result in degradation of
galectin-3 or radixin in either MDCK or T47D cells although both of the cell lines are very
sensitive to DX-52-1 treatment (low nanomolar concentration). Thus, DX-52-1’s inhibition
of cell migration is not due to the degradation of the target proteins. The change of the
localization of the target proteins may contribute to the inhibition of cell migration by the
treatment of DX-52-1. Herein, we investigated whether or not DX-52-1 affects the
localization of galectin-3. In comparing the images from immune fluorescence microscopy,
no clear change was observed on localization of galectin-3 in MDCK, T47D, 4T07 and
MDA-MB-435 cells in the absence or presence of DX-52-1 (Fig.2 A,B,C,D). Quantitative
calculations were carried out by comparing the amount of galectin-3 localized in the
nucleus and cytoplasm, which also exhibited no significant difference in nuclear to
cytoplasmic ratio of the protein. (Fig.2 E). All the data showed here indicates that DX-52-1
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treatment does not alter the localization of galectin-3 in various cell lines in spite of their
sensitivity to the compound. These observations may explanation that DX-52-1 does not
disrupt the interaction between galectin-3 and importin, another protein responsible for
nuclear translocation of galectin-3. Further studies such as the identification of the binding
site of galectin-3 to DX-52-1 will enhance our knowledge on the mechanism of action of
DX-52-1 on its target proteins.
Interestingly, when we examined the organization of actin cytoskeleton on different types
of cell lines including DX-52-1 sensitive and DX-52-1 non-sensitive ones in the absence or
presence of the compound, we found that DX-52-1 disrupted the organization of actin
cytoskeleton on T47D and MDA-MB-435 cells but not 4T07 and Du145 siluc cells. DX52-1 inhibits cell migration by targeting radixin and galectin-3. Radixin, along with ezrin
and moesin, is a non-enzymatic membrane-cytoskeleton linker whose functions have been
implicated in a range of processes, particularly at actin-rich cell-surface structures (for
reviews, see refs. [51-55]). DX-52-1 acts not by inhibiting an enzymatic activity but by
disrupting protein-protein interactions. Yet it may not be the reason here because radixin is
expressed in all of the cell lines being tested. We just found that galectin-3 binds to alphaactinin (unpublished data), an actin binding protein, that plays key role in the organization
of actin cytoskeleton, DX-52-1 disrupts the interaction between them. This gives very
strong evidence to explain why DX-52-1 shows effects in T47D and MDA-MB-435 cells
in which galectin-3 is expressed but not in 4T07 and Du145 siluc cells in which galectin-3
is not detected.
Previously, we proposed that the mechanism of covalent modification of galectin-3 may
involve elimination of the nitrile group of DX-52-1 or HUK-921 followed by the attack of
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a nucleophilic amino acid side chain of galectin-3 on the resulting iminium ion. The
similar mechanism has been proposed also for alkylation of radixin by DX-52-1 [12]. But
the evidence has not been revealed yet. We further investigated the structure-activity
relationship study which can provide much information in understanding the correlation of
the chemical structure and biological activity [56]; moreover, it can facilitate learning the
mechanism of action.
The series of experiments presented here show that the replacement of nitrile group with H or -C≡CH (TMS) on DX-52-1 led to a total loss of its binding ability to the target
proteins (radixin and galectin-3) in vitro and anti-migratory activity to a DX-52-1 sensitive
cell line MDA-MB-435 in vivo. In addition, analogs that are acetylated on the hydroxyl
group significantly reduced the binding ability of the compounds to their target proteins
with no subtoxic activity in cell migration. On the other hand, bromination on the phenyl
ring of the compounds had no effect on either the binding ability in vitro or the antimigratory activity in vivo.
Taken together, these three lines of evidence strongly suggest that the nitrile group is
responsible for the compound’s binding to the target proteins as proposed previously [12].
First, DX-52-1 and its analogs were investigated in competitive binding assays with
radixin and galectin-3. The fact that the analogs with their nitrile group being replaced with
-H or -C≡CH (TMS) lost the ability to bind the two proteins and also lost their antimigratory ability indicates that nitrile group plays important role for the reactivity of the
inhibitor both in vitro and in vivo. This does not necessarily rule out the possibility that
there might be other functional groups contributin to the reactivity as well. Apart from that,
we also found that acetylation on the hydroxyl group caused a statistically significant
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reduction of the reactivity of the analogs in binding assays and anti-migratory activity,
which suggests that the hydroxyl group may contributesin recognition of the target
proteins. Bromination on the phenyl ring, on the other hand, showed no effect in either set
of experiments. Herein, we provide strong evidence that the mechanism of covalent
modification of galectin-3 involves elimination of the nitrile group of DX-52-1 followed
by the attack of a nucleophilic amino acid side chain of galectin-3 on the resulting iminium
ion. The similar mechanism is proposed for alkylation of radixin (Scheme 1).
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Scheme 1. Proposed mechanism of action of DX-52-1 on target proteins
In the future study, a structure-based template can be used to develop inhibitors with
higher sensitivity and greater selectivity towards potential drugs to treat cancers.

Significance
We show that two small molecule inhibitors DX-52-1 and HUK-921 have effects on the
eleven different cancer cell lines in the process of cell migration and cell proliferation.
Among these cell lines, DX-52-1 shows very promising potency on triple-negative human
breast cancer BT-20 and human breast cancer MDA-MB-435 and T47D cells. In addition it
also shows great selectivity over various cancer cell lines. DX-52-1 disrupts the
organization of the actin cytoskeleton of drug-sensitive cell lines but have no effect on
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COOH

non-sensitive ones. Six analogs of DX-52-1 were synthesized and employed in a SAR
study from which we provide strong evidence that the mechanism of covalent modification
of galectin-3 involves elimination of the nitrile group of DX-52-1 followed by the attack of
a nucleophilic amino acid side chain of galectin-3 on the resulting iminium ion. We
propose the similar mechanism for alkylation of radixin. We also found that the hydroxyl
group (-OH) on DX-52-1 (C19) plays a very important role in the recognition of the the
target proteins.
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APPENDIX
DX-52-1 has effect on 4T1
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Figure A1. Time course of wound closure in 4T1 cell monolayers of DX-52-1. Percent
wound closure is depicted as a function of time after treatment with: 0.05% DMSO or
various concentrations of DX-52-1. Each concentration involved at least three separate
experiments each with multiple replicates (n, number of separately treated wounds with
one wound per well on multiwell plates). Percent closure values are means ± standard error
of the mean (SEM). Each concentration was considered a bioactive concentration if there
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test.
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye
exclusion assay, as well as observation of any rounding up of cells in this and subsequent
figures.
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IC50 at 12 Hours for DX on 4T1
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Figure A2. Dose-response curve for DX-52-1’s effect in 4T1 cells wound closure. IC50
values were determined by nonlinear regression analysis with GraphPad Prism software. It
was calculated for inhibition of wound closure at 12 h post-wounding with normalization
to parallel controls using at least 5 different subtoxic concentrations in concentrationresponse experiments. The calculated IC50 value for inhibition of wound closure at 12 h by
DX-52-1 is 30.7 µM.
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Proliferation Assay-4T1
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Figure A3. Dose-response curve for DX-52-1’s anti-proliferatory effect in 4T1 cells.
Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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IC50 of 4T1 for proliferation
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Figure A4. Dose-response curve for DX-52-1’s effect in 4T1 cells proliferation. IC50
values were determined by nonlinear regression analysis with GraphPad Prism software. It
was calculated for inhibition of proliferation at 48 h post-treatment with normalization to
parallel controls using at least 5 different subtoxic concentrations in concentrationresponse experiments. The calculated IC50 value for inhibition of proliferation by DX-52-1
is 695 nM.
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Proliferation Assay- HUK on 4T1
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Figure A5. Dose-response curve for HUK-921’s anti-proliferatory effect in 4T1 cells.
Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A6. Dose-response curve for HUK-921’s effect in 4T1 cells proliferation. IC50
values were determined by nonlinear regression analysis with GraphPad Prism software. It
was calculated for inhibition of proliferation at 48 h post-treatment with normalization to
parallel controls using at least 5 different subtoxic concentrations in concentrationresponse experiments. The calculated IC50 value for inhibition of proliferation by HUK921 is 35.0 µM.
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Proliferation Assay- DX on 4T07
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Figure A7. Dose-response curve for DX-52-1’s anti-proliferatory effect in 4T07 cells.
Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A8. Dose-response curve for DX-52-1’s effect in 4T07 cells proliferation. IC50
values were determined by nonlinear regression analysis with GraphPad Prism software. It
was calculated for inhibition of proliferation at 48 h post-treatment with normalization to
parallel controls using at least 5 different subtoxic concentrations in concentrationresponse experiments. The calculated IC50 value for inhibition of proliferation by DX-52-1
is 2.24 µM.
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Proliferation Assay- HUK on 4T07
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Figure A9. Dose-response curve for HUK-921’s anti-proliferatory effect in 4T07 cells.
Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A10. Dose-response curve for HUK-921’s effect in 4T07 cells proliferation.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of proliferation at 48 h post-treatment with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of
proliferation by HUK-921 is 12.2 µM.
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Figure A11. Dose-response curve for DX-52-1’s anti-proliferatory effect in B16-BL6
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A12. Dose-response curve for DX-52-1’s effect in B16-BL6 cells proliferation.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of proliferation at 48 h post-treatment with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of
proliferation by DX-52-1 is 1.43 µM.

83
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Figure A13. Dose-response curve for HUK-921’s anti-proliferatory effect in B16-BL6
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A14. Dose-response curve for HUK-921’s effect in B16-BL6 cells proliferation.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of proliferation at 48 h post-treatment with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of
proliferation by HUK-921 is 2.48 µM.
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Figure A15. Time course of wound closure in B16-F10 cell monolayers of HUK-921.
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO
or various concentrations of HUK-921. Each concentration involved at least three separate
experiments each with multiple replicates (n, number of separately treated wounds with
one wound per well on multiwell plates). Percent closure values are means ± standard error
of the mean (SEM). Each concentration was considered a bioactive concentration if there
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test.
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye
exclusion assay, as well as observation of any rounding up of cells in this and subsequent
figures.

86

IC50 of B16-F10 for migration
HUK
Percent wound closure

100
80
60
40
20
0
-7.5 -7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0 -3.5

Log [HUK]

IC50 = 19.6 µM

Sigmoidal dose-response (variable slope)
Best-fit values
Bottom
Top
LogEC50
HillSlope
EC50
Std. Error
Bottom
Top
LogEC50
HillSlope
95% Confidence Intervals
Bottom
Top
LogEC50
HillSlope
EC50
Goodness of Fit
Degrees of Freedom
R²
Absolute Sum of Squares
Sy.x
Number of points
Analyzed

-2.857
88.71
-4.708
-1.270
1.957e-005
9.895
2.789
0.1009
0.2958
-22.69 to 16.97
83.12 to 94.30
-4.911 to -4.506
-1.863 to -0.6772
1.229e-005 to 3.118e-005
56
0.8973
7268
11.39
60

Figure A16. Dose-response curve for HUK-921’s effect in B16-F10 cells wound
closure. IC50 values were determined by nonlinear regression analysis with GraphPad
Prism software. It was calculated for inhibition of wound closure at 24 h post-wounding
with normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24h by HUK-921 is 19.6 µM.
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Figure A17. Dose-response curve for HUK-921’s anti-proliferatory effect in B16-F10
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A18. Dose-response curve for HUK-921’s effect in B16-F10 cells proliferation.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of proliferation at 48 h post-treatment with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of
proliferation by HUK-921 is 26.3 µM.
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Figure A19. Dose-response curve for DX-52-1’s anti-proliferatory effect in B16-F10
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A20. Dose-response curve for DX-52-1’s effect in B16-F10 cells proliferation.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of proliferation at 48 h post-treatment with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of
proliferation by DX-52-1 is 1.51 µM.
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Figure A21. Time course of wound closure in BT20 cell monolayers of DX-52-1.
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO
or various concentrations of DX-52-1. Each concentration involved at least three separate
experiments each with multiple replicates (n, number of separately treated wounds with
one wound per well on multiwell plates). Percent closure values are means ± standard error
of the mean (SEM). Each concentration was considered a bioactive concentration if there
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test.
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye
exclusion assay, as well as observation of any rounding up of cells in this and subsequent
figures.
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Figure A22. Dose-response curve for DX-52-1’s effect in BT20 cells wound closure.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of wound closure at 24 h post-wounding with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by DX-52-1 is 687 nM.
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Figure A23. Time course of wound closure in BT20 cell monolayers of HUK-921.
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO
or various concentrations of HUK-921. Each concentration involved at least three separate
experiments each with multiple replicates (n, number of separately treated wounds with
one wound per well on multiwell plates). Percent closure values are means ± standard error
of the mean (SEM). Each concentration was considered a bioactive concentration if there
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test.
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye
exclusion assay, as well as observation of any rounding up of cells in this and subsequent
figures.

94

IC50 at 24 Hours for HUK on BT 20

HUK
Percent Closed at 24 Hours

95

90

85

80

75
-8.0

-7.5

-7.0

-6.5

-6.0

-5.5

-5.0

-4.5

-4.0

Log [HUK]

Sigmoidal dose-response (variable slope)
Best-fit values
Bottom
Top
LogEC50
HillSlope
EC50
Std. Error
Bottom
Top
LogEC50
HillSlope
95% Confidence Intervals
Bottom
Top
LogEC50
HillSlope
EC50
Goodness of Fit
Degrees of Freedom
R square
Absolute Sum of Squares
Sy.x
Number of points
Analyzed

Interrupted
-46672
89.67
9.923
-0.2554
8.367e+009

60

Figure A24. Dose-response curve for HUK-921’s effect in BT20 cells wound closure.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of wound closure at 24 h post-wounding with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24h by HUK-921 is not shown.
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Figure A25. Dose-response curve for DX-52-1’s anti-proliferatory effect in BT20 cells.
Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A26. Dose-response curve for DX-52-1’s effect in BT20 cells proliferation. IC50
values were determined by nonlinear regression analysis with GraphPad Prism software. It
was calculated for inhibition of proliferation at 48 h post-treatment with normalization to
parallel controls using at least 5 different subtoxic concentrations in concentrationresponse experiments. The calculated IC50 value for inhibition of proliferation by DX-52-1
is 1.38 µM.
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Figure A27. Dose-response curve for HUK-921’s anti-proliferatory effect in BT20
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A28. Dose-response curve for HUK-921’s effect in BT20 cells proliferation.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of proliferation at 48 h post-treatment with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of
proliferation by HUK-921 is 7.08 µM.
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Figure A29. Dose-response curve for HUK-921’s anti-proliferatory effect in Du145
siluc cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL).
Medium changed after growing the cells for 24 hrs in the presence or absence of HUK921. After another 48hrs, cell numbers were counted with the Cell Counting Kit-8
(Dojindo), a tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax
Plus384, Molecular devices) based on manufacturer's protocol. Cell numbers are means ±
standard error of the mean (SEM). Each concentration was considered a bioactive
concentration if there was statistically significant inhibition with P < 0.05 by unpaired twotailed Student’s t-test.
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Figure A30. Dose-response curve for HUK-921’s effect in Du145 siluc cells
proliferation. IC50 values were determined by nonlinear regression analysis with
GraphPad Prism software. It was calculated for inhibition of proliferation at 48 h posttreatment with normalization to parallel controls using at least 5 different subtoxic
concentrations in concentration-response experiments. The calculated IC50 value for
inhibition of proliferation by HUK-921 is 11.7 µM.
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Figure A31. Dose-response curve for DX-52-1’s anti-proliferatory effect in Du145
siluc cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL).
Medium changed after growing the cells for 24 hrs in the presence or absence of DX-52-1.
After another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A32. Dose-response curve for DX-52-1’s effect in Du145 siluc cells
proliferation. IC50 values were determined by nonlinear regression analysis with
GraphPad Prism software. It was calculated for inhibition of proliferation at 48 h posttreatment with normalization to parallel controls using at least 5 different subtoxic
concentrations in concentration-response experiments. The calculated IC50 value for
inhibition of proliferation by DX-52-1 is 314 nM.
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Figure A33. Time course of wound closure in 168FARN cell monolayers of HUK-921.
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO
or various concentrations of HUK-921. Each concentration involved at least three separate
experiments each with multiple replicates (n, number of separately treated wounds with
one wound per well on multiwell plates). Percent closure values are means ± standard error
of the mean (SEM). Each concentration was considered a bioactive concentration if there
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test.
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye
exclusion assay, as well as observation of any rounding up of cells in this and subsequent
figures.
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Figure A34. Dose-response curve for HUK-921’s effect in 168FARN cells wound
closure. IC50 values were determined by nonlinear regression analysis with GraphPad
Prism software. It was calculated for inhibition of wound closure at 48h post-wounding
with normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 48h by HUK-921 is 43.5 µM.
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Figure A35. Dose-response curve for DX-52-1’s anti-proliferatory effect on 168FARN
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A36. Dose-response curve for DX-52-1’s effect in 168FARN cells proliferation.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of proliferation at 48 h post-treatment with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of
proliferation by DX-52-1 is 1.96 µM.
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Figure A37. Dose-response curve for HUK-921’s anti-proliferatory effect in
168FARN cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per
mL). Medium changed after growing the cells for 24 hrs in the presence or absence of
HUK-921. After another 48hrs, cell numbers were counted with the Cell Counting Kit-8
(Dojindo), a tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax
Plus384, Molecular devices) based on manufacturer's protocol. Cell numbers are means ±
standard error of the mean (SEM). Each concentration was considered a bioactive
concentration if there was statistically significant inhibition with P < 0.05 by unpaired twotailed Student’s t-test.
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Figure A38. Dose-response curve for HUK-921’s effect in 168FARN cells
proliferation. IC50 values were determined by nonlinear regression analysis with
GraphPad Prism software. It was calculated for inhibition of proliferation at 48 h posttreatment with normalization to parallel controls using at least 5 different subtoxic
concentrations in concentration-response experiments. The calculated IC50 value for
inhibition of proliferation by HUK-921 is 32.9 µM.
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Figure A39. Dose-response curve for HUK-921’s anti-proliferatory effect in MCF7
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A40. Dose-response curve for HUK-921’s effect in MCF7 cells proliferation.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of proliferation at 48 h post-treatment with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of
proliferation by HUK-921 is 10.8 µM.
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Figure A41. Dose-response curve for DX-52-1’s anti-proliferatory effect on MCF7
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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Figure A42. Dose-response curve for DX-52-1’s effect in MCF7 cells proliferation.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of proliferation at 48 h post-treatment with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of
proliferation by DX-52-1 is 176 nM.
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Figure A43. Time course of wound closure in MDA-MB-231 cell monolayers of DX52-1. Percent wound closure is depicted as a function of time after treatment with: 0.05%
DMSO or various concentrations of DX-52-1. Each concentration involved at least three
separate experiments each with multiple replicates (n, number of separately treated wounds
with one wound per well on multiwell plates). Percent closure values are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test. At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye
exclusion assay, as well as observation of any rounding up of cells in this and subsequent
figures.
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Figure A44. Dose-response curve for DX-52-1’s effect in MDA-MB-231 cells wound
closure. IC50 values were determined by nonlinear regression analysis with GraphPad
Prism software. It was calculated for inhibition of wound closure at 24 h post-wounding
with normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by DX-52-1 is 57.4 µM.
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Figure A45. Dose-response
response curve for DX
DX-52-1’s anti-proliferatory
proliferatory effect on MDAMDA
MB-231 cells. Cells were plated into 96
96-well tissue culture plates (4.0 × 104 cells per mL).
Medium changed after growing the cells for 24 hrs in the presence or absence of DX-52-1.
DX
After another 48hrs, cell numbers were counted with the Cell Counting Kit-8
Kit (Dojindo), a
tetrazolium salt-based
based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there wass statistically significant inhibition with P < 0.05 by unpaired two-tailed
two
Student’s
t-test.
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Figure A46. Dose-response
response curve for HUK
HUK-921’s anti-proliferatory
proliferatory effect in MDAMDA
MB-231 cells. Cells were plated into 96
96-well tissue culture plates (4.0 × 104 cells per mL).
Medium changed after growing the cells for 24 hrs in the presence or absence of HUKHUK
921.. After another 48hrs, cell numbers were counted with the Cell Counting Kit-8
Kit
(Dojindo), a tetrazolium
m salt
salt-based
based assay, with an absorbance plate reader (SpectraMax
Plus384, Molecular devices) based on manufacturer's protocol. Cell numbers are means ±
standard error of the mean (SEM). Each concentration was considered a bioactive
concentration if there wass statistically significant inhibition with P < 0.05 by unpaired twotwo
tailed Student’s t-test.
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Figure A47. Dose-response curve for HUK-921’s effect in MDA-MB-231 cells
proliferation. IC50 values were determined by nonlinear regression analysis with
GraphPad Prism software. It was calculated for inhibition of proliferation at 48 h posttreatment with normalization to parallel controls using at least 5 different subtoxic
concentrations in concentration-response experiments. The calculated IC50 value for
inhibition of proliferation by HUK-921 is 27.3 µM.

118
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Figure A48. Time course of wound closure in MDA-MB-435 cell monolayers of DX52-1. Percent wound closure is depicted as a function of time after treatment with: 0.05%
DMSO or various concentrations of DX-52-1. Each concentration involved at least three
separate experiments each with multiple replicates (n, number of separately treated wounds
with one wound per well on multiwell plates). Percent closure values are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test. At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye
exclusion assay, as well as observation of any rounding up of cells in this and subsequent
figures.
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Figure A49. Dose-response curve for DX-52-1’s effect in MDA-MB-435 cells wound
closure. IC50 values were determined by nonlinear regression analysis with GraphPad
Prism software. It was calculated for inhibition of wound closure at 24 h post-wounding
with normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by DX-52-1 is 213 nM.
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Figure A50. Time course of wound closure in MDA-MB-435 cell monolayers of HUK921. Percent wound closure is depicted as a function of time after treatment with: 0.05%
DMSO or various concentrations of HUK-921. Each concentration involved at least three
separate experiments each with multiple replicates (n, number of separately treated wounds
with one wound per well on multiwell plates). Percent closure values are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test. At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye
exclusion assay, as well as observation of any rounding up of cells in this and subsequent
figures.
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Figure A51. Dose-response curve for HUK-921’s effect in MDA-MB-435 cells wound
closure. IC50 values were determined by nonlinear regression analysis with GraphPad
Prism software. It was calculated for inhibition of wound closure at 24h post-wounding
with normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24h by HUK-921 is 24.4 µM.
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Figure A52. Dose-response curve for DX-52-1’s effect in MDA-MB-435 cells
proliferation. IC50 values were determined by nonlinear regression analysis with
GraphPad Prism software. It was calculated for inhibition of proliferation at 48 h posttreatment with normalization to parallel controls using at least 5 different subtoxic
concentrations in concentration-response experiments. The calculated IC50 value for
inhibition of proliferation by DX-52-1 is 163 nM.
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Figure A53. Time course of wound closure in T47D cell monolayers of HUK-921.
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO
or various concentrations of HUK-921. Each concentration involved at least three separate
experiments each with multiple replicates (n, number of separately treated wounds with
one wound per well on multiwell plates). Percent closure values are means ± standard error
of the mean (SEM). Each concentration was considered a bioactive concentration if there
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test.
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye
exclusion assay, as well as observation of any rounding up of cells in this and subsequent
figures.
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Figure A54. Dose-response curve for HUK-921’s effect in T47D cells wound closure.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of wound closure at 36h post-wounding with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 36h by HUK-921 is 44.5 µM.
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Proliferation Assay- HUK on T47D
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Figure A55. Dose-response curve for HUK-921’s anti-proliferatory effect in T47D
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of HUK-921. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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IC50 of T47D for proliferation
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Figure A56. Dose-response curve for HUK-921’s effect in T47D cells proliferation.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of proliferation at 48 h post-treatment with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of
proliferation by HUK-921 is 12.1 µM.

127

Quantitative Wound Closure Assay: DX-52-1 on T47D
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Figure A57. Time course of wound closure in T47D cell monolayers of DX-52-1.
Percent wound closure is depicted as a function of time after treatment with: 0.05% DMSO
or various concentrations of DX-52-1. Each concentration involved at least three separate
experiments each with multiple replicates (n, number of separately treated wounds with
one wound per well on multiwell plates). Percent closure values are means ± standard error
of the mean (SEM). Each concentration was considered a bioactive concentration if there
was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s t-test.
At the end of the experiment, cytotoxicity was evaluated with the Trypan blue dye
exclusion assay, as well as observation of any rounding up of cells in this and subsequent
figures.
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Percent wound closure at 12 h
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Figure A58. Dose-response curve for DX-52-1’s effect in T47D cells wound closure.
IC50 values were determined by nonlinear regression analysis with GraphPad Prism
software. It was calculated for inhibition of wound closure at 36 h post-wounding with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 36 h by DX-52-1 is 53.7 nM.
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Proliferation Assay: T47D
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Figure A59. Dose-response curve for DX-52-1’s anti-proliferatory effect on T47D
cells. Cells were plated into 96-well tissue culture plates (4.0 × 104 cells per mL). Medium
changed after growing the cells for 24 hrs in the presence or absence of DX-52-1. After
another 48hrs, cell numbers were counted with the Cell Counting Kit-8 (Dojindo), a
tetrazolium salt-based assay, with an absorbance plate reader (SpectraMax Plus384,
Molecular devices) based on manufacturer's protocol. Cell numbers are means ± standard
error of the mean (SEM). Each concentration was considered a bioactive concentration if
there was statistically significant inhibition with P < 0.05 by unpaired two-tailed Student’s
t-test.
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IC50 for DX-52-1 on T47D (Proliferation Assay)
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Figure A60. Dose-response curve for DX-52-1’s effect in T47D cells proliferation. IC50
values were determined by nonlinear regression analysis with GraphPad Prism software. It
was calculated for inhibition of proliferation at 48 h post-treatment with normalization to
parallel controls using at least 5 different subtoxic concentrations in concentrationresponse experiments. The calculated IC50 value for inhibition of proliferation by DX-52-1
is 228 nM.
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